Purpose New research findings have revealed a key role for vascular endothelial growth
factor (VEGF) in the stimulation of angiogenesis in clear cell renal carcinoma (RCC) which is …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

Background. Sorafenib is a multikinase inhibitor currently used in the treatment of
hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Objectives. The literature …

Background To evaluate the feasibility and security of complete remission (CR) of advanced
hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

Objective: The current study aimed to investigate the therapeutic efficacy of sorafenib
against primary liver cancer (PLC). Methods: Four databases (PubMed, CNKI, WanFang and …

Abstract Background & Aims The study aimed to evaluate the tissue expression of molecules
involved in intracellular signalling pathways as predictors of response to sorafenib in …

Objective: To investigate the inhibitory effect of AKR1B10 inhibitor combined with sorafenib
on hepatocellular carcinoma (HCC) xenograft growth. Methods: HepG2 xenograft model …

Purpose: Sorafenib has proved survival benefit for patients with advanced hepatocellular
carcinoma (HCC). This study explored whether the efficacy of sorafenib can be improved by …

Purpose: By carrying out a meta-analysis of randomized controlled trials that compared
sorafenib or combined chemotherapy with placebo or combined chemotherapy, the …